Sean McCarthy, CytomX CEO
CytomX halts lead program and will seek a partner as breast cancer drug disappoints
Mixed Phase II results are forcing CytomX to slam the brakes on one of its lead cancer drugs — unless it can convince a partner to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
